Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series

Abstract : Hyperglycaemia may develop after whole-pancreas transplantation (PTX) in patients with type 1 diabetes mellitus (T1DM), but the efficacy and tolerability of GLP-1 receptor agonists have not been assessed in this population. This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA 1c > 6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2 mg once daily at week 1. Gastrointestinal disorders were reported in three of the six patients, with discontinuation of liraglutide in only one patient. HbA 1c improved in the five remaining patients, with a median decrease of 0.8% (0.0-2.7%) at 6 months, and the median decrease in body weight was 2.0 kg. Immunosuppressive treatments remained unchanged with liraglutide. Thus, liraglutide appears to be an effective and well-tolerated option in PTX patients with impaired glucose homoeostasis, regardless of the cause.
Document type :
Journal articles
Complete list of metadatas

Cited literature [7 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02147105
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Tuesday, June 4, 2019 - 2:26:08 PM
Last modification on : Wednesday, June 5, 2019 - 1:27:57 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Bertrand Cariou, C. Bernard, D. Cantarovich. Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series. Journal of Diabetes & Metabolism, OMICS International, 2015, 41 (3), pp.252-257. ⟨10.1016/j.diabet.2014.10.004⟩. ⟨inserm-02147105⟩

Share

Metrics

Record views

42